CAN-BIND-17 Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Summary
Major depressive disorder (MDD) is a common, life-disrupting and highly recurrent illness. Unfortunately, 30–40% of patients do not respond to currently available interventions. The research study we are conducting hopes to shorten the path from diagnosing a person with MDD to starting them on a right, or 'personalized', treatment plan. To achieve this we examine brain scans, clinical assessments and blood samples to gain a better understanding of depression and how best to treat it. we are.
To do so, we are seeking to recruit participants who either have major depressive disorder (MDD) and are currently experiencing symptoms of depression.
We are also recruiting healthy comparison participants.
Eligibility
Eligible gender: Transgender, Other, Male, Female
Eligible ages: 18 to 65
Accepts healthy participants: Yes
Inclusion criteria:
Inclusion criteria:
Patients with MDD must
1. Meet have a confirmed diagnosis of major depressive disorder
2. Agree to stop any medication before starting the study and being prescribed the study medication
3. Be fluent in English to understand the interviews and questionnaires.
Healthy Comparison Participants must
1. Not have a history of any psychiatric disorder
2. Not have any significant physical or medical condition (e.g., arthritis, fibromyalgia)
3. Be fluent in English to understand the interviews and questionnaires.
Exclusion criteria:
Exclusionary criteria include:
1. Bipolar Disorder
2. Substance dependence/abuse in the past 6 months
3. Pregnancy or breastfeeding
4. Neurological disorders or head trauma
5. Having previously failed escitalopram or have shown an intolerance to escitalopram.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Stefanie Hassel Phone: 403-210-7445 Email: canbind@ucalgary.ca
Principal investigator:
Valerie Taylor
Clinical trial:
Yes
REB-ID:
REB21-1606